蓝芩口服液联合利巴韦林治疗小儿手足口病的meta分析

A meta-analysis of effects ofLanqin oral liquid and ribavirin on in fantile hand-foot- mouth disease

目的：系统评价蓝芩口服液联合利巴韦林治疗小儿手足口病的临床疗效。方法检索中国期刊全文数据库（CNKI）、中国生物医学文献数据库（SinoMed）、维普数据库（VIP）、万方科技数据库、EMBase、PubMed、Cochrane 图书馆关于蓝芩口服液联合利巴韦林治疗小儿手足口病的随机对照试验研究（各数据库检索时间均从创建至2014年10月），对纳入蓝芩口服液联合利巴韦林治疗儿童手足口病的文献进行方法学质量评价，并采用RevMan 5.2软件进行meta分析。结果共纳入15篇文献，包括2016例患儿。Meta分析结果显示，蓝芩口服液联合利巴韦林组总有效率与对照组比较差异有统计学意义[OR（95﹪ CI）为5.80（3.94，8.52）]；在退热时间、疱疹消退时间、皮疹消退时间、口腔溃疡好转时间比较，2组差异有统计学意义[MD（95%CI）分别为-1.29（-1.45，-1.13）、-1.88（-2.44，-1.33）、-1.57（-2.36，-0.78）、-1.57（-2.07，-1.08）]。结论基于现有临床证据，蓝芩口服液联合利巴韦林联用治疗小儿手足口病疗效优于利巴韦林单用。但因纳入研究文献数量少，质量不齐，此结论尚需更多大样本、高质量临床随机对照试验予以证实。

Objective To systematically evaluate the clinical efficacy of Lanqin Oral Liquid（LOL）and ribavirin on infantile hand-foot-mouth disease（HFMD）.Methods The randomized controlled trials（RCT）of LOL and ribavirincombined for treating HFMD were retrieved from EMbase, PubMed, CNKI, CBM and VIP（from establish to Oct 2014）, the methodological quality of included literature was evaluated, and data analyses were performed with RevMan 5.2 software.Results Fifteen studies involving 2 016 patients were ultimately identified.The meta-analysis results showed that the effective rate of LOL group was superior to that of the control,OR（95%CI）was 5.80 （3.94, 8.52）, and there were significant differences in the antifebrile time, erythra regression time, herpes regression time and oral ulcer regression time between the groups,MD （95%CI）： -1.29 （-1.45,-1.13）, -1.88 （-2.44,-1.33）, -1.57 （-2.36,-0.78）, -1.57 （-2.07,-1.08）, respectively. Conclusion Based on the present clinical evidence, the meta-analysis results indicate that LOL and ribavirin treating HFMD is effective and safe. However, due to the uneven quality of these included studies, this conclusion need more large sample size and high-quality clinical RCTs to be confirmed.